Novartis and Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156, a Novel Compound Against Multidrug-Resistant Malaria
August 21, 2017
August 21, 2017
BASEL, Switzerland, Aug. 21 -- Novartis issued the following news release:
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by s . . .
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by s . . .